ClinicalTrials.gg

Program

JSKN033

A development code. Also written as “JSKN033 Injection”.

Its studies are mostly in Uterine Cervical Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Alphamab Oncology.

Furthest: phase 3, since Aug 25, 20265 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology54 open or runningphase 3since Aug 25, 2026Dec 22, 2023Dec 31, 2026phase 2 · NCT06770881

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2023First study: phase 2 study in Advanced Solid TumorFirst studyNCT06226766 · 11 enrolled · Australia
  2. Dec 27, 2024Phase 2 study in Advanced Malignant TumorsNCT06770881 · 430 planned
  3. Dec 2, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07283198 · 160 planned
  4. Mar 10, 2026Phase 2 study in Uterine Cervical NeoplasmsNCT07497074 · 78 planned · China
  5. Aug 25, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07797153 · 368 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Advanced Malignant TumorsNCT06770881
  2. Aug 30, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07283198
  3. Oct 2027Primary completion: phase 2 study in Uterine Cervical NeoplasmsNCT07497074
  4. Dec 2028Primary completion: phase 3 study in RecurrenceNCT07797153

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07797153Recurrence · China3Not yet recruitingDec 2028368
NCT07497074Uterine Cervical Neoplasms · China2Not yet recruitingOct 202778
NCT07283198Carcinoma, Non-Small-Cell Lung2Not yet recruitingAug 30, 2027160
NCT06770881Advanced Malignant Tumors2Not yet recruitingDec 31, 2026430
NCT06226766Advanced Solid Tumor · Australia2TerminatedJul 31, 202511

How it is read

Names in the registry

  • “JSKN033”, 3 entries
  • “JSKN033 Injection”, 2 entries

Codes read as this program: JSKN033.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.